|
US7683036B2
(en)
|
2003-07-31 |
2010-03-23 |
Regulus Therapeutics Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
|
|
EP2338996A3
(en)
|
2004-05-04 |
2013-12-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for reducing viral genome amounts in a target cell
|
|
US8592384B2
(en)
|
2005-04-04 |
2013-11-26 |
The Board Of Regents Of The University Of Texas System |
Micro-RNA's that regulate muscle cells
|
|
CA2617581A1
(en)
|
2005-08-01 |
2007-02-08 |
The Ohio State University Research Foundation |
Microrna-based methods for the diagnosis of breast cancer
|
|
WO2007027775A2
(en)
|
2005-08-29 |
2007-03-08 |
Isis Pharmaceuticals, Inc. |
Methods for use in modulating mir-122a
|
|
EP1937280B1
(en)
|
2005-09-12 |
2014-08-27 |
The Ohio State University Research Foundation |
Compositions for the therapy of bcl2-associated cancers
|
|
EP2468899B1
(en)
|
2006-01-05 |
2015-03-11 |
The Ohio State University Research Foundation |
MicroRNA-based methods for the diagnosis of stomach cancers
|
|
AU2007205257B2
(en)
|
2006-01-05 |
2013-07-25 |
The Ohio State University Research Foundation |
MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors
|
|
CN102943108B
(zh)
|
2006-01-05 |
2014-05-21 |
俄亥俄州立大学研究基金会 |
用于肺癌的诊断、预后和治疗的基于微小rna的方法和组合物
|
|
AU2007227423B2
(en)
|
2006-03-20 |
2013-11-07 |
The Ohio State University Research Foundation |
MicroRNA fingerprints during human megakaryocytopoiesis
|
|
EP3502255A1
(en)
*
|
2006-04-03 |
2019-06-26 |
Roche Innovation Center Copenhagen A/S |
Pharmaceutical composition
|
|
WO2007112754A2
(en)
*
|
2006-04-03 |
2007-10-11 |
Santaris Pharma A/S |
Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides
|
|
CN103554205A
(zh)
|
2006-05-05 |
2014-02-05 |
Isis制药公司 |
调节gccr的表达的化合物和方法
|
|
EP2369017B8
(en)
|
2006-07-13 |
2014-03-12 |
The Ohio State University Research Foundation |
Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases
|
|
AU2007281261B2
(en)
|
2006-08-01 |
2013-03-21 |
Board Of Regents Of The University Of Texas System |
Identification of a micro-RNA that activates expression of beta-myosin heavy chain
|
|
EP2090665A2
(en)
|
2006-10-20 |
2009-08-19 |
Exiqon A/S |
Novel human microRNAs associated with cancer
|
|
US8188255B2
(en)
|
2006-10-20 |
2012-05-29 |
Exiqon A/S |
Human microRNAs associated with cancer
|
|
WO2008061537A2
(en)
|
2006-11-23 |
2008-05-29 |
Querdenker Aps |
Oligonucleotides for modulating target rna activity
|
|
CN103555825B
(zh)
|
2007-01-31 |
2015-09-30 |
俄亥俄州立大学研究基金会 |
用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物
|
|
JP2010521193A
(ja)
|
2007-03-22 |
2010-06-24 |
サンタリス ファーマ アー／エス |
Ａｐｏ−ｂ１００発現の阻害のためのｒｎａアンタゴニスト化合物
|
|
DK2149605T3
(da)
|
2007-03-22 |
2013-09-30 |
Santaris Pharma As |
Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
|
|
AU2008232316A1
(en)
*
|
2007-03-26 |
2008-10-02 |
Newcastle Innovation Limited |
Therapeutic targets and molecules
|
|
EP2610347B1
(en)
*
|
2007-04-30 |
2015-04-15 |
The Ohio State University Research Foundation |
Methods of determining the prognosis of a subject with pancreatic cancer
|
|
CA2690643A1
(en)
|
2007-06-14 |
2008-12-18 |
Mirx Therapeutics Aps |
Oligonucleotides for modulation of target rna activity
|
|
EP2719773A3
(en)
*
|
2007-06-15 |
2014-07-30 |
The Ohio State University Research Foundation |
miRNA as marker for acute lamphomic leucemia
|
|
WO2009018492A2
(en)
|
2007-07-31 |
2009-02-05 |
The Board Of Regents Of The University Of Texas System |
Micro-rnas that control myosin expression and myofiber identity
|
|
JP5587777B2
(ja)
|
2007-07-31 |
2014-09-10 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
線維症をモジュレートするマイクロｒｎａファミリー及びその使用
|
|
WO2009018303A2
(en)
|
2007-07-31 |
2009-02-05 |
The Ohio State University Research Foundation |
Methods for reverting methylation by targeting dnmt3a and dnmt3b
|
|
CN103866008B
(zh)
|
2007-08-03 |
2016-06-29 |
俄亥俄州立大学研究基金会 |
编码ncrna的超保守区域
|
|
CA2696887C
(en)
|
2007-08-22 |
2016-06-28 |
The Ohio State University Research Foundation |
Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
|
|
US8440637B2
(en)
|
2007-10-04 |
2013-05-14 |
Santaris Pharma A/S |
Combination treatment for the treatment of hepatitis C virus infection
|
|
AU2013273821B2
(en)
*
|
2007-10-04 |
2016-03-10 |
Roche Innovation Center Copenhagen A/S |
Micromirs
|
|
US20100285471A1
(en)
*
|
2007-10-11 |
2010-11-11 |
The Ohio State University Research Foundation |
Methods and Compositions for the Diagnosis and Treatment of Esphageal Adenocarcinomas
|
|
AU2008316577B2
(en)
|
2007-10-26 |
2014-04-10 |
The Ohio State University Research Foundation |
Methods for identifying fragile histidine triad (FHIT) interaction and uses thereof
|
|
CN101980712B
(zh)
|
2007-10-29 |
2015-02-18 |
雷古拉斯治疗公司 |
用于肝癌治疗的靶向微小rna
|
|
BRPI0818901A2
(pt)
*
|
2007-11-09 |
2015-05-12 |
Univ Texas |
Micro-rnas da família mir-15 modulam sobrevivência de cardiomiócitos e reparo cardíaco
|
|
GB0802754D0
(en)
*
|
2008-02-14 |
2008-03-26 |
Inst Superiore Di Sanito |
Antisense RNA targetting CXCR4
|
|
WO2009105759A2
(en)
*
|
2008-02-21 |
2009-08-27 |
The Board Of Regents Of The University Of Texas System |
Micro-rnas that modulate smooth muscle proliferation and differentiation and uses thereof
|
|
EP2096171A1
(en)
|
2008-02-27 |
2009-09-02 |
Julius-Maximilians-Universität Würzburg |
MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
|
|
US20110034538A1
(en)
*
|
2008-02-28 |
2011-02-10 |
The Ohio State University Research Foundation |
MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Gastric Cancer
|
|
CA2717792A1
(en)
|
2008-03-07 |
2009-09-11 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of microrna related diseases
|
|
US8202848B2
(en)
|
2008-03-17 |
2012-06-19 |
Board Of Regents, The University Of Texas System |
Identification of micro-RNAS involved in neuromuscular synapse maintenance and regeneration
|
|
EP2105145A1
(en)
*
|
2008-03-27 |
2009-09-30 |
ETH Zürich |
Method for muscle-specific delivery lipid-conjugated oligonucleotides
|
|
WO2009133915A1
(ja)
*
|
2008-04-30 |
2009-11-05 |
日本電気株式会社 |
癌マーカー、それを用いた癌の評価方法および評価試薬
|
|
EP2307028B1
(en)
|
2008-06-11 |
2013-10-02 |
The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services |
Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
|
|
CA2728069C
(en)
*
|
2008-06-16 |
2018-01-02 |
Biomedbooster B.V. |
Means and methods for counteracting, delaying and/or preventing heart disease
|
|
CA2728816A1
(en)
|
2008-06-27 |
2009-12-30 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Instit Ute For Biomedical Research |
Prediction of antiviral therapy response
|
|
WO2010012667A1
(en)
|
2008-08-01 |
2010-02-04 |
Santaris Pharma A/S |
Micro-rna mediated modulation of colony stimulating factors
|
|
EP2191834A1
(en)
*
|
2008-11-26 |
2010-06-02 |
Centre National De La Recherche Scientifique (Cnrs) |
Compositions and methods for treating retrovirus infections
|
|
ES2629630T3
(es)
*
|
2008-12-04 |
2017-08-11 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO
|
|
ES2572361T3
(es)
|
2008-12-31 |
2016-05-31 |
Roche Innovation Ct Copenhagen As |
Utilización de oligómeros de ANB antisentido de ApoB para el tratamiento de síndromes coronarios agudos
|
|
NZ594365A
(en)
|
2009-02-04 |
2013-03-28 |
Univ Texas |
Dual targeting of miR-208a or miR-208b and miR-499 in the treatment of cardiac disorders or musculoskeletal disorders
|
|
EP2218458A1
(en)
*
|
2009-02-13 |
2010-08-18 |
Fondazione Telethon |
Molecules able to modulate the expression of at least a gene involved in degradative pathways and uses thereof
|
|
AU2010234806B2
(en)
|
2009-03-31 |
2014-05-22 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services |
Differentially expressed microRNAs as biomarkers for the diagnosis and treatment of Sjogren's syndrome
|
|
EP2421970B1
(en)
|
2009-04-24 |
2016-09-07 |
Roche Innovation Center Copenhagen A/S |
Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
|
|
AU2010250838B2
(en)
|
2009-05-20 |
2016-01-21 |
Eth Zurich |
Targeting microRNAs for metabolic disorders
|
|
WO2010135714A2
(en)
*
|
2009-05-22 |
2010-11-25 |
The Methodist Hospital Research Institute |
Methods for modulating adipocyte expression using microrna compositions
|
|
EP2456870A1
(en)
|
2009-07-21 |
2012-05-30 |
Santaris Pharma A/S |
Antisense oligomers targeting pcsk9
|
|
US20110190372A1
(en)
*
|
2009-08-07 |
2011-08-04 |
New York University |
Compositions and methods for treating inflammatory disorders
|
|
WO2011022316A1
(en)
*
|
2009-08-20 |
2011-02-24 |
The Regents Of The University Of Colorado, A Body Corporate |
Mirnas dysregulated in triple-negative breast cancer
|
|
CN102002493B
(zh)
*
|
2009-09-01 |
2013-04-10 |
中国科学院上海生命科学研究院 |
小rna-326制备药物的应用
|
|
WO2011032100A1
(en)
*
|
2009-09-11 |
2011-03-17 |
Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Inhibitors of kshv vil6 and human il6
|
|
US8975019B2
(en)
*
|
2009-10-19 |
2015-03-10 |
University Of Massachusetts |
Deducing exon connectivity by RNA-templated DNA ligation/sequencing
|
|
US9364495B2
(en)
|
2009-10-20 |
2016-06-14 |
Roche Innovation Center Copenhagen A/S |
Oral delivery of therapeutically effective LNA oligonucleotides
|
|
CN102803511A
(zh)
|
2009-11-23 |
2012-11-28 |
俄亥俄州立大学 |
用于影响肿瘤细胞生长、迁移和侵袭的材料和方法
|
|
US20120302626A1
(en)
|
2009-12-04 |
2012-11-29 |
Sandeep Dave |
Microrna and use thereof in identification of b cell malignancies
|
|
JP2013530160A
(ja)
*
|
2010-01-20 |
2013-07-25 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
赤血球増加症治療用ａｎｔｉｍｉＲ−４５１
|
|
WO2011111715A1
(ja)
*
|
2010-03-09 |
2011-09-15 |
協和発酵キリン株式会社 |
細胞周期を制御する核酸
|
|
ES2743600T3
(es)
|
2010-03-12 |
2020-02-20 |
Brigham & Womens Hospital Inc |
Métodos de tratamiento de los trastornos inflamatorios vasculares
|
|
WO2011117353A1
(en)
*
|
2010-03-24 |
2011-09-29 |
Mirrx Therapeutics A/S |
Bivalent antisense oligonucleotides
|
|
SG184821A1
(en)
*
|
2010-04-21 |
2012-11-29 |
Amc Amsterdam |
Means and methods for determining risk of cardiovascular disease
|
|
EP2563935B1
(en)
|
2010-04-30 |
2014-04-16 |
Exiqon A/S |
In situ hybridization method and buffer.
|
|
US20110281933A1
(en)
*
|
2010-05-13 |
2011-11-17 |
Saint Louis University |
Methods and compositions for the management of cardiovascular disease with oligonucleotides
|
|
FR2960130B1
(fr)
|
2010-05-21 |
2013-11-01 |
Dominique Cingotti |
Agent edulcorant contenant un extrait de stevia rebaudiana bertoni
|
|
US20130210883A1
(en)
|
2010-05-21 |
2013-08-15 |
Johannes Grillari |
Lipase inhibitors
|
|
BR112012029656A2
(pt)
|
2010-05-21 |
2016-12-13 |
Uni Fur Bodenkultur Wien |
composições para uso no tratamento ou diagnóstico de disturbios ósseos e/ou distúrbios cardiovasculares
|
|
AU2011261213B2
(en)
*
|
2010-06-04 |
2015-05-21 |
Board Of Regents, The University Of Texas System |
Regulation of metabolism by miR-378
|
|
US20130150256A1
(en)
|
2010-06-11 |
2013-06-13 |
Jane Synnergren |
Novel micrornas for the detection and isolation of human embryonic stem cell-derived cardiac cell types
|
|
EP2594643B1
(en)
|
2010-07-12 |
2017-04-12 |
National University Corporation Tottori University |
Method for producing novel hipsc by means of sirna introduction
|
|
WO2012012716A2
(en)
|
2010-07-23 |
2012-01-26 |
Regulus Therapeutics, Inc. |
Targeting micrornas for the treatment of fibrosis
|
|
US8859519B2
(en)
|
2010-08-25 |
2014-10-14 |
The General Hospital Corporation |
Methods targeting miR-33 microRNAs for regulating lipid metabolism
|
|
AU2011293195A1
(en)
|
2010-08-27 |
2013-04-11 |
New York University |
MiR-33 inhibitors and uses thereof
|
|
WO2012048113A2
(en)
|
2010-10-07 |
2012-04-12 |
The General Hospital Corporation |
Biomarkers of cancer
|
|
CN102031261B
(zh)
*
|
2010-10-27 |
2015-04-22 |
南京医科大学 |
一种与妊娠期糖尿病相关的血清/血浆miRNA标志物及其应用
|
|
EP2638159B1
(en)
*
|
2010-11-11 |
2019-04-24 |
University of Miami |
Compositions, kits and methods for treatment of cardiovascular, immunological, and inflammatory diseases
|
|
JP6336755B2
(ja)
|
2010-11-12 |
2018-06-06 |
ザ ジェネラル ホスピタル コーポレイション |
ポリコームに関連する非コードｒｎａ
|
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
|
EP2638912A4
(en)
|
2010-11-12 |
2015-01-21 |
Nat Univ Corp Ehime Univ |
COMPOSITIONS WITH AN ANTISENSE OLIGONUCLEOTIDE AGAINST MICRO RNA
|
|
AU2011326032B2
(en)
|
2010-11-12 |
2016-10-06 |
The Ohio State University Research Foundation |
Materials and methods related to microRNA-21, mismatch repair, and colorectal cancer
|
|
BR112013011942A2
(pt)
|
2010-11-15 |
2016-11-01 |
Univ Michigan |
formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida.
|
|
CN102041316A
(zh)
*
|
2010-11-30 |
2011-05-04 |
华东师范大学 |
miRNA-219化合物作为脑胶质瘤标志物的应用
|
|
AR084319A1
(es)
*
|
2010-12-15 |
2013-05-08 |
Miragen Therapeutics |
INHIBIDORES DE microARN (miARN O miR) QUE COMPRENDEN NUCLEOTIDOS BLOQUEADOS
|
|
US9308217B2
(en)
|
2010-12-20 |
2016-04-12 |
Agency For Science, Technology And Research |
Targeting glioma stem cells by sequence-specific functional inhibition of pro-survival oncomir-138
|
|
US9045749B2
(en)
|
2011-01-14 |
2015-06-02 |
The General Hospital Corporation |
Methods targeting miR-128 for regulating cholesterol/lipid metabolism
|
|
CN102174516A
(zh)
*
|
2011-01-20 |
2011-09-07 |
中南大学 |
一种与ebv感染相关的鼻咽癌诊断和治疗的分子靶标及其应用
|
|
JP2014509852A
(ja)
*
|
2011-03-07 |
2014-04-24 |
ジ・オハイオ・ステート・ユニバーシティ |
マイクロＲＮＡ−１５５（ｍｉＲ−１５５）により誘導される変異誘発活性は炎症および癌を結び付ける
|
|
EP2697374A2
(en)
*
|
2011-04-12 |
2014-02-19 |
Beth Israel Deaconess Medical Center, Inc. |
Micro-rna inhibitors and their uses in disease
|
|
WO2012145374A1
(en)
|
2011-04-19 |
2012-10-26 |
Regulus Therapeutics Inc. |
TARGETING miR-378 FAMILY MEMBERS FOR THE TREATMENT OF METABOLIC DISORDERS
|
|
TWI698445B
(zh)
*
|
2011-04-25 |
2020-07-11 |
法商賽諾菲公司 |
微型ｒｎａ化合物及調控ｍｉｒ－２１活性之方法
|
|
US9241950B2
(en)
|
2011-04-28 |
2016-01-26 |
New York University |
MiR-33 inhibitors and uses thereof to decrease inflammation
|
|
EP2723863A1
(en)
|
2011-06-23 |
2014-04-30 |
Stella ApS |
Hcv combination therapy
|
|
WO2012175357A1
(en)
*
|
2011-06-24 |
2012-12-27 |
Syddansk Universitet |
Modulation of microrna-138 for the treatment of bone loss
|
|
KR20140058536A
(ko)
|
2011-06-30 |
2014-05-14 |
스텔라 에이피에스 |
Hcv 조합 치료
|
|
JP2014520772A
(ja)
|
2011-06-30 |
2014-08-25 |
ステラ・アンパルトセルスカブ |
Ｈｃｖ併用療法
|
|
CN102908621A
(zh)
*
|
2011-08-02 |
2013-02-06 |
中国科学院上海生命科学研究院 |
miRNAs作为调节胰岛素敏感性的靶标的新用途
|
|
US9434944B2
(en)
|
2011-08-31 |
2016-09-06 |
University Of Zurich |
Modulators of miR-323-3p for the prevention or treatment of rheumatoid arthritis
|
|
CN102978278B
(zh)
*
|
2011-09-07 |
2016-09-28 |
中国科学院动物研究所 |
内源性的非编码小RNAs及其应用
|
|
DK2756080T3
(da)
|
2011-09-14 |
2019-05-20 |
Translate Bio Ma Inc |
Multimeriske oligonukleotidforbindelser
|
|
US9428749B2
(en)
|
2011-10-06 |
2016-08-30 |
The Board Of Regents, The University Of Texas System |
Control of whole body energy homeostasis by microRNA regulation
|
|
CA2851280C
(en)
|
2011-10-11 |
2021-05-18 |
The Brigham And Women's Hospital, Inc. |
Micrornas in neurodegenerative disorders
|
|
GB201117482D0
(en)
*
|
2011-10-11 |
2011-11-23 |
Univ Dundee |
Targetiing of miRNA precursors
|
|
AU2012323924A1
(en)
|
2011-10-14 |
2014-05-29 |
The Ohio State University |
Methods and materials related to ovarian cancer
|
|
WO2013068348A1
(en)
|
2011-11-07 |
2013-05-16 |
Santaris Pharma A/S |
Lna oligomers for improvement in hepatic function
|
|
EP2776590B1
(en)
|
2011-11-07 |
2016-10-26 |
Roche Innovation Center Copenhagen A/S |
Prognostic method for checking efficacy of micro rna-122 inhibitors in hcv+ patients
|
|
CN104619353A
(zh)
*
|
2011-12-13 |
2015-05-13 |
俄亥俄州国家创新基金会 |
与miR-21和miR-29a相关的方法和组合物、外切体抑制和癌症转移
|
|
US20140356459A1
(en)
*
|
2011-12-15 |
2014-12-04 |
Oncostamen S.R.L. |
Micrornas and uses thereof
|
|
US9447471B2
(en)
*
|
2011-12-29 |
2016-09-20 |
Quest Diagnostics Investments Incorporated |
Microrna profiling for diagnosis of dysplastic nevi and melanoma
|
|
AU2013209477B2
(en)
|
2012-01-20 |
2016-12-08 |
The Ohio State University |
Breast cancer biomarker signatures for invasiveness and prognosis
|
|
JP6322189B2
(ja)
*
|
2012-04-25 |
2018-05-09 |
レグルス セラピューティクス インコーポレイテッド |
Ｍｉｒ−２１活性を調節するためのマイクロｒｎａ化合物及び方法
|
|
US9334498B2
(en)
|
2012-05-10 |
2016-05-10 |
Uab Research Foundation |
Methods and compositions for modulating MIR-204 activity
|
|
CA2873779A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics Inc. |
Compositions and methods for modulating mecp2 expression
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
CA2873797A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics Inc. |
Compositions and methods for modulating utrn expression
|
|
EA201492123A1
(ru)
|
2012-05-16 |
2015-10-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии семейства генов smn
|
|
AU2013262699A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating ATP2A2 expression
|
|
JP2015518714A
(ja)
|
2012-05-16 |
2015-07-06 |
ラナ セラピューティクス インコーポレイテッド |
遺伝子発現を調節するための組成物及び方法
|
|
AP2014008100A0
(en)
|
2012-05-16 |
2014-12-31 |
Gen Hospital Corp |
Compositions and methods for modulating hemoglobingene family expression
|
|
CA2876180C
(en)
*
|
2012-06-21 |
2019-11-19 |
MiRagen Therapeutics, Inc. |
Oligonucleotide-based inhibitors comprising locked nucleic acid motif
|
|
US9163235B2
(en)
|
2012-06-21 |
2015-10-20 |
MiRagen Therapeutics, Inc. |
Inhibitors of the miR-15 family of micro-RNAs
|
|
US10316367B2
(en)
|
2012-06-21 |
2019-06-11 |
Ruprecht-Karls-Universität Heidelberg |
Circulating miRNAs as markers for breast cancer
|
|
US9845465B2
(en)
|
2012-08-15 |
2017-12-19 |
University Of Virginia Patent Foundation |
Compositions and methods for treating peripheral arterial disease
|
|
EP2886122B1
(en)
*
|
2012-08-20 |
2019-02-27 |
National Cancer Center |
Agent for treating cancer
|
|
US20150247141A1
(en)
|
2012-09-14 |
2015-09-03 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotide compounds
|
|
UA116639C2
(uk)
|
2012-10-09 |
2018-04-25 |
Рег'Юлес Терап'Ютікс Інк. |
Способи лікування синдрому альпорта
|
|
CA2890045C
(en)
*
|
2012-10-31 |
2016-11-15 |
The Rockefeller University |
Treatment and diagnosis of colon cancer
|
|
JP2016503300A
(ja)
|
2012-11-15 |
2016-02-04 |
ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ |
抗ＡｐｏＢアンチセンス複合体化合物
|
|
WO2014082644A1
(en)
*
|
2012-11-30 |
2014-06-05 |
WULFF, Peter, Samuel |
Circular rna for inhibition of microrna
|
|
CN104955952A
(zh)
|
2013-01-30 |
2015-09-30 |
弗·哈夫曼-拉罗切有限公司 |
Lna寡核苷酸碳水化合物缀合物
|
|
WO2014118272A1
(en)
|
2013-01-30 |
2014-08-07 |
Santaris Pharma A/S |
Antimir-122 oligonucleotide carbohydrate conjugates
|
|
US9752143B2
(en)
|
2013-03-15 |
2017-09-05 |
MiRagen Therapeutics, Inc. |
Locked nucleic acid inhibitor of miR-145 and uses thereof
|
|
KR20150131365A
(ko)
|
2013-03-15 |
2015-11-24 |
미라젠 세러퓨틱스 인코포레이티드 |
브리지드 바이사이클릭 뉴클레오시드
|
|
WO2014144844A1
(en)
|
2013-03-15 |
2014-09-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
|
|
AU2014259953B2
(en)
|
2013-05-01 |
2020-07-02 |
Regulus Therapeutics Inc. |
Compounds and methods for enhanced cellular uptake
|
|
AU2014259954B2
(en)
|
2013-05-01 |
2019-11-07 |
Regulus Therapeutics Inc. |
MicroRNA compounds and methods for modulating miR-122
|
|
CN103293318B
(zh)
*
|
2013-05-22 |
2014-10-29 |
吉林大学 |
利用地高辛标记EDC交联桥连法检测miRNAs方法
|
|
US10053690B2
(en)
|
2013-06-12 |
2018-08-21 |
New York University |
Anti-miR-27b and anti-miR-148a oligonucleotides as therapeutic tools for treating dyslipidemias and cardiovascular diseases
|
|
US9976140B2
(en)
|
2013-06-14 |
2018-05-22 |
Joslin Diabetes Center, Inc. |
Microrna and uses in brown fat differentiation
|
|
DK3013959T3
(da)
|
2013-06-27 |
2020-02-17 |
Roche Innovation Ct Copenhagen As |
Antisense-oligomerer og konjugater målrettet pcsk9
|
|
EP3024933A4
(en)
*
|
2013-07-24 |
2017-03-15 |
The General Hospital Corporation |
Agents and methods for inhibiting mir-148a for the modulation of cholesterol levels
|
|
WO2015020122A1
(ja)
*
|
2013-08-08 |
2015-02-12 |
国立大学法人 大阪大学 |
尿路上皮癌の診断または治療剤
|
|
EP3060664B1
(en)
|
2013-10-25 |
2021-07-07 |
Sanofi |
Microrna compounds and methods for modulating mir-21 activity
|
|
US9458458B2
(en)
|
2013-11-11 |
2016-10-04 |
Emory University |
Manipulating microRNA for the management of neurological diseases or conditions and compositions related thereto
|
|
US20160362688A1
(en)
*
|
2014-02-12 |
2016-12-15 |
Thomas Jefferson University |
Compositions and methods of using microrna inhibitors
|
|
WO2015175539A1
(en)
|
2014-05-12 |
2015-11-19 |
The Johns Hopkins University |
Engineering synthetic brain penetrating gene vectors
|
|
WO2015175545A1
(en)
|
2014-05-12 |
2015-11-19 |
The Johns Hopkins University |
Highly stable biodegradable gene vector platforms for overcoming biological barriers
|
|
WO2015200697A1
(en)
|
2014-06-25 |
2015-12-30 |
The General Hospital Corporation |
Targeting human satellite ii (hsatii)
|
|
EP3177722A4
(en)
*
|
2014-07-31 |
2018-01-17 |
Agency For Science, Technology And Research |
Modified antimir-138 oligonucleotides
|
|
BR112017001931A2
(pt)
|
2014-08-07 |
2017-11-28 |
Regulus Therapeutics Inc |
direcionamento de micrornas para distúrbios metabólicos
|
|
EP3230453B1
(en)
|
2014-09-21 |
2020-05-20 |
Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. |
Downregulating mir-132 for the treatment of lipid related disorders
|
|
CN104306988B
(zh)
*
|
2014-09-25 |
2017-02-15 |
中国医学科学院基础医学研究所 |
miR‑431在制备治疗肌肉疾病的药物中的用途
|
|
WO2016070060A1
(en)
|
2014-10-30 |
2016-05-06 |
The General Hospital Corporation |
Methods for modulating atrx-dependent gene repression
|
|
JP2017534281A
(ja)
|
2014-11-10 |
2017-11-24 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
潰瘍性大腸炎に特異的な診断および予後予測のバイオマーカーとしてのｍｉｒ−２１４ならびに潰瘍性大腸炎治療のためのｍｉｒ−２１４阻害剤
|
|
DK3218386T3
(da)
*
|
2014-11-14 |
2021-06-07 |
Voyager Therapeutics Inc |
Modulatorisk polynukleotid
|
|
MX2017006216A
(es)
|
2014-11-14 |
2018-08-29 |
Voyager Therapeutics Inc |
Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
|
|
EP3020813A1
(en)
|
2014-11-16 |
2016-05-18 |
Neurovision Pharma GmbH |
Antisense-oligonucleotides as inhibitors of TGF-R signaling
|
|
SG10201906716QA
(en)
|
2015-01-20 |
2019-08-27 |
Miragen Therapeutics Inc |
Mir-92 inhibitors and uses thereof
|
|
US10758558B2
(en)
|
2015-02-13 |
2020-09-01 |
Translate Bio Ma, Inc. |
Hybrid oligonucleotides and uses thereof
|
|
US10900036B2
(en)
|
2015-03-17 |
2021-01-26 |
The General Hospital Corporation |
RNA interactome of polycomb repressive complex 1 (PRC1)
|
|
US10961532B2
(en)
|
2015-04-07 |
2021-03-30 |
The General Hospital Corporation |
Methods for reactivating genes on the inactive X chromosome
|
|
RU2718534C2
(ru)
*
|
2015-06-05 |
2020-04-08 |
Мираджен Терапьютикс, Инк. |
Ингибиторы mir-155 для лечения кожной t-клеточной лимфомы (ctcl)
|
|
WO2016196978A1
(en)
*
|
2015-06-05 |
2016-12-08 |
MiRagen Therapeutics, Inc. |
Mir-155 inhibitors for treating amyotrophic lateral sclerosis (als)
|
|
US20180161429A1
(en)
|
2015-06-26 |
2018-06-14 |
Beth Israel Deaconess Medical Center Inc. |
Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
|
|
EP3331546B1
(en)
|
2015-08-03 |
2023-10-04 |
Biokine Therapeutics Ltd. |
Cxcr4 inhibitor for the treatment of cancer
|
|
CN107922945A
(zh)
|
2015-08-24 |
2018-04-17 |
罗氏创新中心哥本哈根有限公司 |
Lna‑g 方法
|
|
CA2997786A1
(en)
*
|
2015-09-22 |
2017-03-30 |
MiRagen Therapeutics, Inc. |
Mir-19 modulators and uses thereof
|
|
EP3355932B1
(en)
|
2015-10-02 |
2023-04-12 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugation process
|
|
WO2017062659A1
(en)
*
|
2015-10-06 |
2017-04-13 |
University Of Virginia Patent Foundation |
Compositions and methods for treating diabetic retinopathy
|
|
JP6666002B2
(ja)
|
2015-10-07 |
2020-03-13 |
国立大学法人京都大学 |
Ｔｄｐ−４３プロテノパシーの予防又は治療用組成物
|
|
WO2017066712A2
(en)
|
2015-10-16 |
2017-04-20 |
The Children's Medical Center Corporation |
Modulators of telomere disease
|
|
US10955407B2
(en)
|
2015-10-22 |
2021-03-23 |
Roche Innovation Center Copenhagen A/S |
In vitro toxicity screening assay
|
|
AU2016355178B9
(en)
|
2015-11-19 |
2019-05-30 |
Massachusetts Institute Of Technology |
Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
|
|
JOP20200228A1
(ar)
|
2015-12-21 |
2017-06-16 |
Novartis Ag |
تركيبات وطرق لخفض تعبير البروتين tau
|
|
CN107012199A
(zh)
*
|
2016-01-28 |
2017-08-04 |
上海市东方医院 |
一种在血浆和血清中检测miRNA的方法
|
|
WO2017147087A1
(en)
|
2016-02-25 |
2017-08-31 |
The Brigham And Women's Hospital, Inc. |
Treatment methods for fibrosis targeting smoc2
|
|
US11267843B2
(en)
|
2016-03-18 |
2022-03-08 |
Roche Innovation Center Copenhagen A/S |
Stereodefining L-monomers
|
|
CN109311925B
(zh)
|
2016-05-12 |
2022-06-03 |
罗氏创新中心哥本哈根有限公司 |
立体限定的氧杂氮杂磷杂环戊烷亚磷酰胺单体与核苷或寡核苷酸的增强的偶联
|
|
IL302748A
(en)
|
2016-05-18 |
2023-07-01 |
Voyager Therapeutics Inc |
modulatory polynucleotides
|
|
CN109831916B
(zh)
|
2016-05-18 |
2023-07-21 |
沃雅戈治疗公司 |
治疗亨廷顿氏舞蹈病的组合物和方法
|
|
US11015196B2
(en)
|
2016-05-20 |
2021-05-25 |
The General Hospital Corporation |
Using microRNAs to control activation status of hepatic stellate cells and to prevent fibrosis in progressive liver diseases
|
|
WO2017216340A1
(en)
|
2016-06-17 |
2017-12-21 |
F. Hoffmann-La Roche Ag |
In vitro nephrotoxicity screening assay
|
|
EP3472347B1
(en)
|
2016-06-17 |
2023-01-04 |
F. Hoffmann-La Roche AG |
In vitro nephrotoxicity screening assay
|
|
US11253601B2
(en)
|
2016-07-11 |
2022-02-22 |
Translate Bio Ma, Inc. |
Nucleic acid conjugates and uses thereof
|
|
JP2019521176A
(ja)
|
2016-07-18 |
2019-07-25 |
ジャーン バイオセラピューティクス エルエルシーＪａａｎ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｌｃ |
心疾患の処置のための組成物及び方法
|
|
US20220354888A1
(en)
|
2016-08-03 |
2022-11-10 |
Aalborg Universitet |
ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
|
|
WO2018080658A1
(en)
*
|
2016-10-27 |
2018-05-03 |
Aalborg University |
Therapeutic targeting of a microrna to treat duchenne muscular dystrophy
|
|
EP3532638A4
(en)
|
2016-10-31 |
2020-07-29 |
University of Massachusetts |
TARGETING MICROARN-101-3 P IN CARCINOTHERAPY
|
|
CN110290794A
(zh)
|
2016-11-01 |
2019-09-27 |
纽约州州立大学研究基金会 |
5-卤代尿嘧啶修饰的微rna及其在癌症治疗中的用途
|
|
KR20190096414A
(ko)
|
2016-12-22 |
2019-08-19 |
오하이오 스테이트 이노베이션 파운데이션 |
체세포를 유도된 혈관형성 세포로 재프로그래밍하기 위한 조성물 및 방법
|
|
US11591362B2
(en)
|
2017-03-29 |
2023-02-28 |
Roche Innovation Center Copenhagen A/S |
Orthogonal protecting groups for the preparation of stereodefined phosphorothioate oligonucleotides
|
|
CN110446718A
(zh)
|
2017-03-29 |
2019-11-12 |
罗氏创新中心哥本哈根有限公司 |
Unylinker快速裂解
|
|
US20200384115A1
(en)
|
2017-04-21 |
2020-12-10 |
The Broad Institute , Inc. |
Targeted delivery to beta cells
|
|
US11752181B2
(en)
|
2017-05-05 |
2023-09-12 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating Huntington's disease
|
|
CN110913866A
(zh)
|
2017-05-05 |
2020-03-24 |
沃雅戈治疗公司 |
治疗肌萎缩性侧索硬化(als)的组合物和方法
|
|
JP7492829B2
(ja)
|
2017-06-28 |
2024-05-30 |
ロシュ イノベーション センター コペンハーゲン エーエス |
多重カップリングおよび酸化の方法
|
|
WO2019073018A1
(en)
|
2017-10-13 |
2019-04-18 |
Roche Innovation Center Copenhagen A/S |
METHODS OF IDENTIFYING ANTISENSE OLIGONUCLEOTIDE IMPROVED OLIGONUCLEOTIDE PHOSPHOROTHIOATE STEREODEFINIS VARIANTS USING PARTIALLY STEREODEFINIS OLIGONUCLEOTIDE SUB LIBRARIES
|
|
US20200237799A1
(en)
|
2017-10-16 |
2020-07-30 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
JP7502991B2
(ja)
|
2017-10-16 |
2024-06-19 |
ボイジャー セラピューティクス インコーポレイテッド |
筋萎縮性側索硬化症（ａｌｓ）の治療
|
|
EP3703669A4
(en)
|
2017-11-01 |
2021-11-10 |
Dana-Farber Cancer Institute, Inc. |
CANCER TREATMENT METHODS
|
|
CN108272815B
(zh)
*
|
2017-12-06 |
2020-09-11 |
南方医科大学深圳医院 |
EB病毒miR-BART10-5p抑制剂的应用
|
|
CN108220381A
(zh)
*
|
2017-12-07 |
2018-06-29 |
国家卫生计生委科学技术研究所 |
试剂在制备药物中的用途以及筛选药物的方法
|
|
TW201929870A
(zh)
|
2017-12-22 |
2019-08-01 |
丹麥商羅氏創新中心哥本哈根有限公司 |
包含二硫代磷酸酯核苷間連結之寡核苷酸
|
|
JP2021508327A
(ja)
|
2017-12-22 |
2021-03-04 |
ロシュ イノベーション センター コペンハーゲン エーエス |
新規のチオホスホラミダイト
|
|
JP7476101B2
(ja)
|
2017-12-22 |
2024-04-30 |
ロシュ イノベーション センター コペンハーゲン エーエス |
ホスホロジチオアートヌクレオシド間結合を含むギャップマーオリゴヌクレオチド
|
|
EP3765610A4
(en)
|
2018-03-14 |
2022-01-19 |
Beth Israel Deaconess Medical Center |
MICRO-RNA AND OBESITY
|
|
CN108220427B
(zh)
*
|
2018-03-20 |
2021-09-28 |
南京大学 |
一种用于鉴别诊断BHD综合征与原发性自发性气胸的血浆microRNA标记物及应用
|
|
JP7279081B2
(ja)
|
2018-05-08 |
2023-05-22 |
レグルス セラピューティクス インコーポレイテッド |
Ｍｉｒ－１２２を調節するためのマイクロｒｎａ化合物及び方法
|
|
EP3793685A1
(en)
*
|
2018-05-18 |
2021-03-24 |
F. Hoffmann-La Roche AG |
Pharmaceutical compositions for treatment of microrna related diseases
|
|
US11679100B2
(en)
|
2018-05-30 |
2023-06-20 |
The Regents Of The University Of California |
Methods of enhancing immunity
|
|
CN110777199B
(zh)
*
|
2018-07-24 |
2023-11-14 |
长庚医疗财团法人高雄长庚纪念医院 |
干癣性关节炎的诊断及治疗及其相应的试剂盒
|
|
ES2924362T3
(es)
|
2018-07-31 |
2022-10-06 |
Roche Innovation Ct Copenhagen As |
Oligonucleótidos que comprenden un enlace internucleosídico fosforotritioato
|
|
EP3830101A1
(en)
|
2018-07-31 |
2021-06-09 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
|
JP7499754B2
(ja)
|
2018-08-23 |
2024-06-14 |
ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブ |
Ｍｉｃｒｏｒｎａ－１３４バイオマーカー
|
|
CA3110661A1
(en)
|
2018-08-29 |
2020-03-05 |
University Of Massachusetts |
Inhibition of protein kinases to treat friedreich ataxia
|
|
EP3620519A1
(en)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
|
|
CN110468202A
(zh)
*
|
2019-01-18 |
2019-11-19 |
宁夏医科大学 |
一种靶向TIGIT的miR-206作为肝癌诊断和治疗新型分子的用途
|
|
EP3914232A1
(en)
|
2019-01-25 |
2021-12-01 |
F. Hoffmann-La Roche AG |
Lipid vesicle for oral drug delivery
|
|
CA3129646A1
(en)
|
2019-02-20 |
2020-08-27 |
Roche Innovation Center Copenhagen A/S |
Novel phosphoramidites
|
|
TW202102516A
(zh)
|
2019-02-20 |
2021-01-16 |
丹麥商羅氏創新中心哥本哈根有限公司 |
膦醯基乙酸酯間隙子寡核苷酸
|
|
EP3904518A4
(en)
*
|
2019-02-26 |
2023-10-11 |
Seoul National University R & DB Foundation |
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING TUT4/7 EXPRESSION MODULATOR
|
|
JP7503072B2
(ja)
|
2019-02-26 |
2024-06-19 |
ロシュ イノベーション センター コペンハーゲン エーエス |
オリゴヌクレオチドの製剤化方法
|
|
BR112021023488A2
(pt)
|
2019-05-31 |
2022-01-18 |
Aligos Therapeutics Inc |
Oligonucleotídeos de gapmer modificados e métodos de uso
|
|
WO2020261227A1
(en)
|
2019-06-26 |
2020-12-30 |
Biorchestra Co., Ltd. |
Micellar nanoparticles and uses thereof
|
|
CN110548041A
(zh)
*
|
2019-08-30 |
2019-12-10 |
中国医科大学附属盛京医院 |
LNA-anti-miR-150在制备预防或治疗肾脏纤维化药物中的用途
|
|
CN111057790B
(zh)
*
|
2019-12-11 |
2022-08-30 |
石河子大学 |
miRNA在制备用于检测KSHV潜伏感染的试剂盒中的用途
|
|
EP4110916A1
(en)
|
2020-02-28 |
2023-01-04 |
F. Hoffmann-La Roche AG |
Oligonucleotides for modulating cd73 exon 7 splicing
|
|
EP4129338A4
(en)
*
|
2020-03-02 |
2024-04-10 |
Mitsubishi Tanabe Pharma Corporation |
PREVENTION OR TREATMENT OF ANEURYSMS WITH MIR-33B INHIBITOR
|
|
KR102555878B1
(ko)
*
|
2020-04-23 |
2023-07-17 |
주식회사 바이오오케스트라 |
하향조절된 mirna의 진단 및 치료를 위한 용도
|
|
WO2021251526A1
(ko)
*
|
2020-06-11 |
2021-12-16 |
주식회사 프로스테믹스 |
신규한 mirna 유사체 및 이의 용도
|
|
CN112301130B
(zh)
*
|
2020-11-12 |
2021-11-30 |
苏州京脉生物科技有限公司 |
一种肺癌早期检测的标志物、试剂盒及方法
|
|
AU2022219031A1
(en)
|
2021-02-12 |
2023-09-07 |
Merand Pharmaceuticals, Inc. |
Agents, compositions, and methods for the treatment of hypoxia and ischemia-related disorders
|
|
JP2024522272A
(ja)
|
2021-06-04 |
2024-06-13 |
ニューミルナ セラピューティクス エーピーエス |
アデノシンキナーゼを標的とするアンチセンスオリゴヌクレオチド
|
|
WO2022260162A1
(ja)
*
|
2021-06-11 |
2022-12-15 |
国立大学法人京都大学 |
Ｎａｓｈの予防及び／又は治療剤
|
|
EP4105328A1
(en)
|
2021-06-15 |
2022-12-21 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Antisense-oligonucleotides for prevention of kidney dysfunction promoted by endothelial dysfunction by ephrin-b2 suppression
|
|
WO2023013818A1
(ko)
*
|
2021-08-06 |
2023-02-09 |
주식회사 네오나 |
변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료용 조성물
|
|
KR102329524B1
(ko)
*
|
2021-08-06 |
2021-11-23 |
주식회사 네오나 |
변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료용 조성물
|
|
WO2023021184A1
(en)
|
2021-08-19 |
2023-02-23 |
Neumirna Therapeutics Aps |
Antisense oligonucleotides targeting adenosine kinase
|
|
WO2023060238A2
(en)
*
|
2021-10-08 |
2023-04-13 |
Regulus Therapeutics Inc. |
Methods and compositions for avoiding off-target effects
|
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
|
US20240182561A1
(en)
|
2022-11-04 |
2024-06-06 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
WO2024112653A1
(en)
*
|
2022-11-22 |
2024-05-30 |
The Regents Of The University Of California |
Inhibitory nucleic acids and methods of use thereof
|
